Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
REGENXBIO Inc. RGNX
$18.92
-$0.28 (-1.46%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
835420364.00000000
-
week52high
35.73
-
week52low
17.03
-
Revenue
112724000
-
P/E TTM
-3
-
Beta
1.07474000
-
EPS
-6.75000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 10:59
Описание компании
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 10 авг 2022 г. |
| UBS | Buy | Buy | 23 июн 2022 г. |
| Berenberg | Buy | 23 июн 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 24 мая 2022 г. |
| Chardan Capital | Buy | Buy | 05 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 09 сент 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 04 окт 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 04 ноя 2022 г. |
| Chardan Capital | Buy | Buy | 04 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 21 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Christmas Patrick J. | A | 56519 | 56519 | 03 янв 2023 г. |
| Christmas Patrick J. | A | 89037 | 67940 | 03 янв 2023 г. |
| Christmas Patrick J. | D | 21097 | 1843 | 03 янв 2023 г. |
| Danos Olivier | A | 52986 | 52986 | 03 янв 2023 г. |
| Danos Olivier | A | 92950 | 65930 | 03 янв 2023 г. |
| Danos Olivier | D | 27020 | 2058 | 03 янв 2023 г. |
| Mills Kenneth T. | A | 264932 | 264932 | 03 янв 2023 г. |
| Mills Kenneth T. | A | 355289 | 54753 | 03 янв 2023 г. |
| Mills Kenneth T. | D | 300536 | 9308 | 03 янв 2023 г. |
| PAKOLA STEVE | A | 44155 | 44155 | 03 янв 2023 г. |
Новостная лента
REGENXBIO to Participate in Upcoming Investor Conferences
PRNewsWire
08 мая 2023 г. в 07:05
ROCKVILLE, Md. , May 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: BofA Securities 2023 Health Care Conference Fireside Chat Date: Wednesday, May 10, 2023 Fireside Chat Time: 5:00 p.m.
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?
The Motley Fool
15 апр 2023 г. в 08:20
RegenxBio has several collaborations with other pharmaceutical companies. The company doesn't have its own wholly owned product but receives plenty of royalty revenue.
REGENXBIO to Participate in Upcoming Investor Conferences
PRNewsWire
08 мар 2023 г. в 07:05
ROCKVILLE, Md. , March 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Barclays Global Healthcare Conference Fireside Chat Date: Wednesday, March 15, 2023 Fireside Chat Time: 5:00 p.m.
REGENXBIO Inc. (RGNX) Q4 2022 Earnings Call Transcript
Seeking Alpha
28 февр 2023 г. в 22:36
REGENXBIO Inc. (NASDAQ:RGNX ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve Pakola - Chief Medical Officer Vit Vasista - Chief Financial Officer Conference Call Participants Dane Leone - Raymond James Lisa Walter - RBC Capital Markets Andreas Argyrides - Wedbush Securities Caroline Palomeque - Berenberg Operator Hello, and thank you for standing by. Welcome to the Q4 and Full Year 2022 REGENXBIO Earnings Call.
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
28 февр 2023 г. в 21:50
Regenxbio (RGNX) delivered earnings and revenue surprises of 6.76% and 12.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?